Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene B2M
Variant LOH
Impact List deletion
Protein Effect unknown
Gene Variant Descriptions B2M LOH indicates the loss of one parental copy of the B2M gene, resulting in loss of heterozygosity.
Associated Drug Resistance
Category Variants Paths

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
B2M LOH melanoma predicted - resistant Ipilimumab Clinical Study - Cohort Actionable In a retrospective analysis, B2M loss of heterozygosity (LOH) was significantly enriched in pre-treatment biopsies of melanoma patients who did not respond to Yervoy (ipilimumab) compared to those who responded (20/69, 28.9% vs 4/36, 11.1%, p=0.01), and was associated with poorer overall survival (p=0.01) (PMID: 29070816). 29070816
B2M LOH melanoma predicted - resistant Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, the presence of B2M loss of heterozygosity (LOH) in the pre-treatment biopsies was significantly associated with worse overall survival (p=0.006) in melanoma patients treated with Keytruda (pembrolizumab) (PMID: 29070816). 29070816